Nicola Thompson, Trimtech Therapeutics CEO (Photo: PIR International)
Lilly, Pfizer invest in UK startup's seed round for neurodegeneration protein degraders
A UK startup that wants to bring protein degraders to the neurodegeneration field has closed a $31 million seed round.
The company is called Trimtech …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
